Fatal oral anticoagulant‐related intracranial hemorrhage: a systematic review and meta‐analysis

Intracranial hemorrhage (ICH) is the most feared complication in patients treated with oral anticoagulants due to non‐valvular atrial fibrillation. Non‐vitamin K oral anticoagulants (NOACs) reduce the risk of ICH compared with vitamin K antagonists (VKAs). We performed a systematic review and meta‐analysis to evaluate the risk of fatal NOAC‐related ICH compared with VKA‐related ICH.

[1]  Eric E. Smith,et al.  Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality , 2018, JAMA.

[2]  G. Breithardt,et al.  Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). , 2017, The American journal of cardiology.

[3]  A. Alexandrov,et al.  Direct oral anticoagulant– vs vitamin K antagonist–related nontraumatic intracerebral hemorrhage , 2017, Neurology.

[4]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal — Full Cohort Analysis , 2017, The New England journal of medicine.

[5]  H. Diener,et al.  Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection , 2017, International journal of stroke : official journal of the International Stroke Society.

[6]  D. Adams.  Idarucizumab for Dabigatran Reversal Full Cohort Analysis , 2017 .

[7]  S. Connolly,et al.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. , 2016, The New England journal of medicine.

[8]  E. Antman,et al.  Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) , 2016, Stroke.

[9]  A. Alexandrov,et al.  Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis , 2016, Therapeutic Advances in Neurological Disorders.

[10]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal. , 2015, The New England journal of medicine.

[11]  Bcps,et al.  Idarucizumab for dabigatran reversal , 2015 .

[12]  Jun Zhu,et al.  Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. , 2015, European heart journal.

[13]  S. Yusuf,et al.  Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial , 2012, Stroke.

[14]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[15]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[16]  R. Hart,et al.  Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. , 1995, Stroke.